Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 4
2020 4
2021 3
2022 5
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapy in cervix cancer.
Attademo L, Tuninetti V, Pisano C, Cecere SC, Di Napoli M, Tambaro R, Valabrega G, Musacchio L, Setola SV, Piccirillo P, Califano D, Spina A, Losito S, Greggi S, Pignata S. Attademo L, et al. Among authors: tuninetti v. Cancer Treat Rev. 2020 Nov;90:102088. doi: 10.1016/j.ctrv.2020.102088. Epub 2020 Aug 7. Cancer Treat Rev. 2020. PMID: 32827839 Review.
Veliparib: a new therapeutic option in ovarian cancer?
Ghisoni E, Giannone G, Tuninetti V, Genta S, Scotto G, Aglietta M, Sangiolo D, Mittica G, Valabrega G. Ghisoni E, et al. Among authors: tuninetti v. Future Oncol. 2019 Jun;15(17):1975-1987. doi: 10.2217/fon-2018-0883. Epub 2019 May 10. Future Oncol. 2019. PMID: 31074636 Review.
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer.
Giannone G, Tuninetti V, Ghisoni E, Genta S, Scotto G, Mittica G, Valabrega G. Giannone G, et al. Among authors: tuninetti v. Int J Mol Sci. 2019 May 12;20(9):2353. doi: 10.3390/ijms20092353. Int J Mol Sci. 2019. PMID: 31083638 Free PMC article. Review.
Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
Turinetto M, Valsecchi AA, Tuninetti V, Scotto G, Borella F, Valabrega G. Turinetto M, et al. Among authors: tuninetti v. Int J Mol Sci. 2022 Mar 24;23(7):3559. doi: 10.3390/ijms23073559. Int J Mol Sci. 2022. PMID: 35408919 Free PMC article. Review.
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis.
Musacchio L, Valsecchi AA, Salutari V, Valabrega G, Camarda F, Tuninetti V, Giannone G, Bartoletti M, Marchetti C, Pignata S, Fagotti A, Scambia G, Di Maio M, Lorusso D. Musacchio L, et al. Among authors: tuninetti v. Cancer Treat Rev. 2022 Nov;110:102458. doi: 10.1016/j.ctrv.2022.102458. Epub 2022 Aug 24. Cancer Treat Rev. 2022. PMID: 36063572 Review.
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Musacchio L, Turinetto M, Arenare L, Bartoletti M, Califano D, Tuninetti V, Marchetti C, Cormio G, Loizzi V, Pisano C, Salutari V, Valabrega G, Priolo D, Cecere SC, Ventriglia J, Raspagliesi F, Perrone F, Fagotti A, Lorusso D, Scambia G, Pignata S. Musacchio L, et al. Among authors: tuninetti v. Gynecol Oncol. 2023 May;172:72-77. doi: 10.1016/j.ygyno.2023.03.011. Epub 2023 Mar 23. Gynecol Oncol. 2023. PMID: 36965291
Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Arezzo F, Giannone G, Castaldo D, Scotto G, Tuninetti V, Turinetto M, Bartoletti M, Mammoliti S, Artioli G, Mangili G, Salutari V, Lorusso D, Cormio G, Loizzi V, Zamagni C, Savarese A, Di Maio M, Ronzino G, Pisano C, Pignata S, Valabrega G. Arezzo F, et al. Among authors: tuninetti v. Front Oncol. 2023 Sep 14;13:1247291. doi: 10.3389/fonc.2023.1247291. eCollection 2023. Front Oncol. 2023. PMID: 37781174 Free PMC article.
26 results